CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER (cefepime hydrochloride) by B. Braun is 12. Approved for pneumonia (moderate to severe) caused by streptococcus pneumoniae (including cases associated with concurrent bacteremia), pseudomonas aeruginosa, klebsiella pneumoniae and 4 more indications. First approved in 2010.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Cefepime and Dextrose in Duplex Container is a fourth-generation cephalosporin antibiotic administered intravenously for moderate-to-severe bacterial infections. It treats pneumonia, skin/skin structure infections, and sepsis caused by Gram-positive and Gram-negative organisms through inhibition of bacterial cell wall synthesis. The duplex container formulation combines cefepime hydrochloride with dextrose for ready-to-use IV administration.
This product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team consolidation and focus on cost-containment strategies rather than growth initiatives.
12.1 Mechanism of Action Cefepime is a cephalosporin antibacterial drug [see ]. 12.2 Pharmacodynamics Similar to other beta-lactam antimicrobial agents, the time that the unbound plasma concentration of cefepime exceeds the MIC of the infecting organism has been shown to best correlate with…
Worked on CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on cefepime at LOE approaching stage offers limited growth trajectory but valuable experience in defensive market positioning, hospital relationships, and generic competition management. Roles emphasize cost optimization, formulary management, and price defense rather than innovation or market expansion.